RE:RE:RE:RE:WEBCAST REPLAY FROM ARCHIVEGV, excellent observation.
Let's remember that on the Zenith side of things Don was very firm in his Q1 2015 update about an IPO on the NASDAQ in Q4 2015. Well, it turns out that there was nothing to IPO.
Now, of course we have the zen3694 mCRPC trial well into dosing but I don't believe that the enzaluimide part of the trial has started. Strong positive results on that trial could attract Pfizer or provide the opportunity for the first Star in SanFrans Start Factory concept. However, this is a very long way off into the future.
So in terms of Don's statement re the next licensing agreement I would not count on anything near term. It could happen and it could be a blockbuster. Certainly the volume and share price run up in September is a signal that information is out there and some parties have bought in.
Of course the next regional deal could be very good for us holders of Zenith Capital.
I'm still a believer in the science but we still do not have one proven clinical trial so I understand why BP and investors are sitting back.
Any one of the well described triggers (CKD, futility analysis, regional deal, mCRPC, orphan trials, NASDAQ, etc) could begin to rocket the stock but none of those events can be predicted so it's wait and see.
What happened yesterday was another good presentation in NYC followed by a share price drop. Don's statement once again raises uncertainty.
I remain long because of the science and because Don will ultimately get his part done and move the business to the enxt stage.
GLTA
Toinv